In Down syndrome patients, these deficiency increases the susceptibility to recurrent infections.71 Therefore, Nisihara et al recommended the future using of mannose-binding lectins therapy.72 Kolb et al also pointed to the suppressive effect of Concanavalin A on inbred mouse model type 1diabetes after low-dose streptozotocin.73,74. Here, MBL2 is linked to Down syndrome.